Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
AURA

AURA - Aura Biosciences, Inc. Stock Price, Fair Value and News

$6.39+0.18 (+2.90%)
Delayed as of 12 Jun 2026, 04:00 pm ET

15/100

AURA

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

15/100

AURA

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

AURA Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

AURA Price Action

Last 7 days

-3.6%

Last 30 days

-20.3%

Last 90 days

7.6%

Trailing 12 Months

-4.2%

AURA RSI Chart

AURA Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

AURA Valuation

Market Cap

409.9M

Price/Earnings (Trailing)

-3.65

Price/Sales (Trailing)

65.83

EV/EBITDA

-2.92

Price/Free Cashflow

-4.47

AURA Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

AURA Fundamentals

AURA Revenue

Revenue (TTM)

6.2M

Rev. Growth (Yr)

-25.35%

Rev. Growth (Qtr)

-22.93%

AURA Earnings

Earnings (TTM)

-112.4M

Earnings Growth (Yr)

-22.57%

Earnings Growth (Qtr)

-31.79%

AURA Profitability

EBT Margin

-1803.32%

Return on Equity

-104.8%

Return on Assets

-81.64%

Free Cashflow Yield

-22.36%

AURA Investor Care

Shares Dilution (1Y)

27.73%

Diluted EPS (TTM)

-1.72

AURA Alerts

  • 1 major insider sales recently.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20266.2M000
20258.3M7.6M7.1M6.6M
20249.3M9.7M10.0M9.4M
20233.8M5.5M7.0M8.6M
2022475.5K938.0K1.4M1.9M
202100013.0K
Get all data in R, Python etc through our Historical Stock Data APIs

About Aura Biosciences, Inc.

AURA
Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for treating tumors of high unmet need in ocular and urologic oncology. It is developing AU-011, a VDC candidate for the treatment of primary choroidal melanoma that is in phase III clinical trial. The company also develops AU-011 for additional ocular oncology indications, including choroidal metastases and is in Phase 2 dose-escalation trial. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.
 CEO
 WEBSITEaurabiosciences.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES70

Aura Biosciences, Inc. Frequently Asked Questions

AURA is the stock ticker symbol of Aura Biosciences, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Jun 12 2026, market cap of Aura Biosciences, Inc. is 409.92 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Jun 12 2026, AURA's PE ratio (Price to Earnings) is -3.65 and Price to Sales (PS) ratio is 65.83. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AURA PE ratio will change depending on the future growth rate expectations of investors.